The largest database of trusted experimental protocols

Zucker lean rats

Manufactured by Charles River Laboratories
Sourced in Spain, Japan

The Zucker Lean (ZL) rats are a well-established animal model used in research. These rats have a normal leptin receptor and do not develop obesity or diabetes, making them a suitable control for studies involving metabolic disorders.

Automatically generated - may contain errors

6 protocols using zucker lean rats

1

Isolated Obese Zucker Rat Heart

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male Obese Zucker Rats (fa/fa, OZR) and their counterpart, Lean Zucker Rats (fa/-, LZR) were provided from Charles River Laboratories (Barcelona, Spain). Animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and euthanized by decapitation and exsanguination. The depth of anesthesia was evaluated by pinching the animal's paw with forceps and all efforts were made to minimize suffering. The heart was quickly removed and placed in cold (4°C) physiological saline solution (PSS) of the following composition (mM): 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 1.5 CaCl2, 24.9 NaHCO3, 0.027 EDTA, and 11 glucose; bubbled with a mixture of 95% O2 and 5% CO2, resulting in a pH 7.4.
+ Open protocol
+ Expand
2

Zucker Rat Metabolic Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
All procedures were conducted according to the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals and approved by
the Institutional Animal Care and Use Committee of the Veterans Affairs Medical
Center (East Orange, New Jersey). Male ZDF (N=12) and lean (+/?) Zucker rats
(N=12) were obtained from Charles River Laboratories (Kingston, NY) at
approximately 6 weeks of age. All rats were single housed upon arrival, with
modest enrichment (a PVC tube). Rats were provided ad libitum access to food and
water and maintained in a 12 h light/dark cycle with lights on at 0630. All
procedures occurred during the light phase of the cycle.
+ Open protocol
+ Expand
3

Linagliptin Treatment in Zucker Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male ZO and age-matched Zucker Lean (ZL) rats were purchased from Charles River, Inc and housed in a 12 hour light/dark altered room. Animals were cared for in accordance with National Institutes of Health guidelines. All procedures were approved and performed in accordance with the Institutional Animal Care and Use Committee of the University of Missouri. Linagliptin (BI 1356; (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin2-ylmethyl)-3,7-dihydro-purine-2,6-dione) was administered orally by mixing drug with rat chow (24 (link)). The final concentration of linagliptin in chow was 83 mg LGT•kg−1 a concentration chosen to achieve a dose and plasma level of approximately 4 mg•kg−1•day−1 and 50–100 nM, respectively (24 (link)). Rats were divided into four groups to include ZL control (ZL-C), ZL treated with linagliptin (ZL-L), ZO control (ZO-C) and ZO treated with linagliptin (ZO-L). Rats were weighed immediately prior to the start of the experiment (8 weeks of age) and every week thereafter until the end of the experiment (16 weeks of age) to monitor weight gain.
+ Open protocol
+ Expand
4

Zucker Obese Rat Model Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sixty-four male Zucker Obese (ZO) and six age-matched Zucker Lean (ZL) rats were purchased from Charles River, Inc and housed in a 12 h light/dark cycled room. Animals were cared for in accordance with the National Institutes of Health guidelines. All procedures were approved and performed in accordance with Subcommittee for Animal Safety of the Harry S Truman Veterans Administration and the Institutional Animal Care and Use Committee of the University of Missouri. All ZO rats were weighed prior to the start of the experiment and distributed into four treatment groups so that each group had a similar mean body weight. Beginning at 16 weeks of age, ZO rats received either sac/val (ZOSV) (68 mg kg−1 day−1), valsartan (ZOV) (31 mg kg−1 day−1), hydralazine (ZOH) (30 mg kg−1 day−1) or saline (ZOC) once daily for 10 weeks by oral gavage. Rats were gavaged at the same time each morning (6:00–7:00 a.m. central standard time). Body weights were measured every week thereafter until the end of the experiment (26 weeks of age). Untreated age-matched male ZL rats served as lean controls (ZLC). Six rats were removed from the study due to complications associated with oral gavage.
+ Open protocol
+ Expand
5

Linagliptin Treatment in Zucker Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male ZO and age-matched Zucker Lean (ZL) rats were purchased from Charles River, Inc and housed in a 12 hour light/dark altered room. Animals were cared for in accordance with National Institutes of Health guidelines. All procedures were approved and performed in accordance with the Institutional Animal Care and Use Committee of the University of Missouri. Linagliptin (BI 1356; (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin2-ylmethyl)-3,7-dihydro-purine-2,6-dione) was administered orally by mixing drug with rat chow (24 (link)). The final concentration of linagliptin in chow was 83 mg LGT•kg−1 a concentration chosen to achieve a dose and plasma level of approximately 4 mg•kg−1•day−1 and 50–100 nM, respectively (24 (link)). Rats were divided into four groups to include ZL control (ZL-C), ZL treated with linagliptin (ZL-L), ZO control (ZO-C) and ZO treated with linagliptin (ZO-L). Rats were weighed immediately prior to the start of the experiment (8 weeks of age) and every week thereafter until the end of the experiment (16 weeks of age) to monitor weight gain.
+ Open protocol
+ Expand
6

Animal Care Protocol for Metabolic Disorders

Check if the same lab product or an alternative is used in the 5 most similar protocols
All experimental procedures were approved by the institutional animal care and use committee of Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) and animal care was conducted in accordance with institutional guidelines. Male KK-Ay mice were purchased from CLEA Japan (Tokyo, Japan), and male Zucker diabetic fatty (ZDF) rats and Zucker lean (ZL) rats were purchased from Charles River Laboratories Japan (Tokyo, Japan). The animals were individually housed in plastic cages with ad libitum access to standard chow (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water. The animal rooms were controlled for temperature (23 ± 3°C), humidity (55 ± 20%), and a 12-h light/dark cycle. These animals were acclimated for 1 week prior to the start of the studies.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!